32 results about "Nicotine replacement" patented technology

Formulations of nicotine for use in nicotine replacement therapy. The formulations are intended for application in the oral cavity where upon the uptake of nicotine mainly takes place through the buccal mucosa. The formulations essentially comprise apolar, polar and surface-active components. The formulations may be administered in combination with other nicotine formulations.

The present invention provides several smoking and tobacco use cessation devices and methods which entirely eliminate the requirement of ignition and burning of substances which emit harmful substances and vapors while simultaneously providing therapeutically efficacious amounts of nicotine and / or nicotine substitutes, and optionally tobacco aroma and taste and / or other undesirable habit inhibiting compounds and antagonists and other desirable orally ingestible substances.

Nicotine in base or salt form combined with cosmetic ingredients to form a lip balm or similar stick. The stick is readily dispensed not only onto a person's lips but also may be used on the skin, for example on the wrist. Packaging the nicotine this way enables a smoker to obtain nicotine discretely anywhere in public, without offending others by smoking. Furthermore, the dosage is readily controlled, and the person's hands and mouth are active, similar to the lighting and smoking of a cigarette.

A method for producing a consumable nicotine-alternative composition includes measuring a quantity of a cigarette nicotine-alternative alkaloid and / or a larger quantity of lobeline. The quantities of cigarette nicotine-alternative alkaloid and / or lobeline are diluted into one or more successive intermediate solutions, a last of which constitutes a final solution. The final solution is apportioned so that each portion contains a precise quantity of cigarette nicotine-alternative alkaloid and / or lobeline appropriate for consumption in a single use by a single person. Each portion is introduced into a separate single-serving dispenser.

Tobacco products comprising smokeless tobacco products and active ingredients, including those that antagonize nicotinic acetylcholine receptors, the TRPV1 channel, and / or the TRPA1 channel are disclosed. Nicotine replacement therapies comprising active ingredients, including those that antagonize nicotinic acetylcholine receptors, the TRPV1 channel, and / or the TRPA1 channel. The active ingredient may reduce or eliminate sensory irritation arising due to use of the product. Analgesic compositions comprising active ingredients. Methods of reducing taste and sensory irritation by employing an active ingredient.

The disclosed invention relates to visual content indicators of a tobacco product. More specifically, the invention includes labeling systems that provide at least one visual indicator of a tobacco product, methods for using the systems, and tobacco products that display one or more visual indicators of content. The present invention generally relates to tobacco products, which have a reduced amount of nicotine and tobacco specific nitrosamines (TSNAs), and contain one or more nicotine substitutes. The use of these tobacco products to reduce the exposure of an individual to nicotine, as well as, facilitating tobacco-use cessation is disclosed.

A composition containing 1,3-propanediol for use as electronic cigarette liquid. A liquid composition for an electronic cigarette, including 1,3-propanediol, as well as at least one compound selected from nicotine, a nicotine substitute, and an aroma, and an electronic cigarette containing this composition.

The disclosed invention relates to visual content indicators of a tobacco product. More specifically, the invention includes labeling systems that provide at least one visual indicator of a tobacco product, methods for using the systems, and tobacco products that display one or more visual indicators of content. The present invention generally relates to tobacco products, which have a reduced amount of nicotine and tobacco specific nitrosamines (TSNAs), and contain one or more nicotine substitutes. The use of these tobacco products to reduce the exposure of an individual to nicotine, as well as, facilitating tobacco-use cessation is disclosed.

The present invention relates to iontophoretic transdermal delivery of nicotine salts useful for nicotine replacement therapy for an individual in need thereof. The present invention further relates to the iontophoretic transdermal delivery of nicotine maleate and nicotine citrate. Methods of reducing skin irritation generally caused by transdermal nicotine delivery by iontophoretic transdermal delivery of nicotine salts are also disclosed.

Provided is a composition containing a polyol that has 4 to 8 carbon atoms and 2 hydroxyl functions that can be used as a liquid for electronic cigarettes. The disclosure further relates to a liquid composition for electronic cigarettes, the composition containing a polyol that has 4 to 8 carbon atoms and 2 hydroxyl functions, as well as at least one compound selected from among nicotine, a nicotine substitute and an aroma. The disclosure also relates to an electronic cigarette containing the composition.

The present invention relates to soft pastilles for nicotine replacement therapy, said pastille comprises about 0.05% to about 1% of nicotine active; about 5% to about 40% of gelling agent; about 30% to about 70% of plasticizer; about 0.05% to about 10% of sweetener; 0.5% to about 30% of releasing agent; about 0.05% to about 2% of preservative; about 0.01% to 5% of flavouring agent; and about 5% to about 20% of water.

The invention described herein relates to an oral transmucosal solid dosage form useful in treating nicotine addiction or as a nicotine substitute or replacement. By virtue of the formulation in combination with nicotine, the invention transmucosally delivers an effective amount of nicotine to the recipient while permitting the accomplishing of such, and manufacture of such, using a relatively small, convenient and orally comfortable dosage form (e.g., tablet) size.

A method for producing a consumable nicotine-alternative composition includes measuring a quantity of a cigarette nicotine-alternative alkaloid and / or a larger quantity of lobeline. The quantities of cigarette nicotine-alternative alkaloid and / or lobeline are diluted into one or more successive intermediate solutions, a last of which constitutes a final solution. The final solution is apportioned so that each portion contains a precise quantity of cigarette nicotine-alternative alkaloid and / or lobeline appropriate for consumption in a single use by a single person. Each portion is introduced into a separate single-serving dispenser.

A method for predicting nicotine replacement dosage to achieve a target nicotine serum concentration relies on measuring blood nicotine concentration prior to smoking cessation. At least two values corresponding to other patient characteristics, such as body mass, cumulative smoking, psychological dependence, age, and menopausal status, are also determined and used to predict expected blood nicotine concentrations based on nicotine replacement dosages. Such methods are useful in achieving target blood nicotine concentrations for smoking cessation and therapy.

The invention relates to the use of a composition containing 1, 3-propanediol as an electronic cigarette liquid. The invention also relates to a liquid composition for electronic cigarettes comprising 1, 3-propanediol, as well as at least one compound selected from nicotine, a nicotine substitute and an aroma. The invention also relates to an electronic cigarette containing said composition.

The present invention relates to a nicotine-containing pharmaceutical composition and methods of using the composition in therapies, such as nicotine replacement therapy.

The invention described herein relates to an oral transmucosal solid dosage form useful in treating nicotine addiction or as a nicotine substitute or replacement. By virtue of the formulation in combination with nicotine, the invention transmucosally delivers an effective amount of nicotine to the recipient while permitting the accomplishing of such, and manufacture of such, using a relatively small, convenient and orally comfortable dosage form (e.g., tablet) size.

The invention relates to the technical field of nicotine replacement therapy products, and discloses a nicotine granule composition, which mainly comprises nicotine quick-release granules and nicotinesustained-release granules, and the nicotine quick-release granules mainly comprise a nicotine raw material, a filler, an adhesive, a buffer agent, a sweetener and an edible essence; the nicotine sustained-release granules mainly comprise the following components: a nicotine raw material, a polymer sustained-release material, an adhesive, a buffer agent, a sweetener and an edible essence. The invention also discloses a method for preparing the nicotine granule mixture and a preparation device thereof. The nicotine granule composition provided by the invention can guarantee the speed of obtaining pleasant sensation of a human body and the duration of nicotine maintaining the concentration with a treatment effect in a human body through the nicotine quick-release granules and the nicotine sustained-release granules, so that smoking addicts can get rid of the dependence on smoking better, and has a better treatment effect than the similar products sold on the market.

The present invention relates to soft pastilles for nicotine replacement therapy, said pastille comprises about 0.05% to about 1% of nicotine active; about 5% to about 40% of gelling agent; about 30% to about 70% of plasticizer; about 0.05% to about 10% of sweetener; 0.5% to about 30% of releasing agent; about 0.05% to about 2% of preservative; about 0.01% to 5% of flavoring agent; and about 5% to about 20% of water.

The invention described herein relates to an oral transmucosal solid dosage form useful in treating nicotine addiction or as a nicotine substitute or replacement. By virtue of the formulation in combination with nicotine, the invention transmucosally delivers an effective amount of nicotine to the recipient while permitting the accomplishing of such, and manufacture of such, using a relatively small, convenient and orally comfortable dosage form (e.g., tablet) size.

The invention relates to the use of a composition containing a polyol that comprises 4 to 8 carbon atoms and 2 hydroxyl functions, as a liquid for electronic cigarettes. The invention further relates to a liquid composition for electronic cigarettes, containing a polyol that comprises 4 to 8 carbon atoms and 2 hydroxyl functions, as well as at least one compound selected from among nicotine, a nicotine substitute and an aroma. The invention also relates to an electronic cigarette containing said composition.

The invention relates to the technical field of nicotine replacement therapy products, and discloses a nicotine granule composition, which mainly comprises nicotine quick-release granules and nicotinesustained-release granules, and the nicotine quick-release granules mainly comprise a nicotine raw material, a filler, an adhesive, a buffer agent, a sweetener and an edible essence; the nicotine sustained-release granules mainly comprise the following components: a nicotine raw material, a polymer sustained-release material, an adhesive, a buffer agent, a sweetener and an edible essence. The invention also discloses a method for preparing the nicotine granule mixture and a preparation device thereof. The nicotine granule composition provided by the invention can guarantee the speed of obtaining pleasant sensation of a human body and the duration of nicotine maintaining the concentration with a treatment effect in a human body through the nicotine quick-release granules and the nicotine sustained-release granules, so that smoking addicts can get rid of the dependence on smoking better, and has a better treatment effect than the similar products sold on the market.

A method for delivering a drug to a user including an electronic cigarette wherein the electronic cigarette itself includes a liquid formulation. The liquid formulation can include at least one drug and at least one biologically acceptable carrier. The at least one drug can be formed with an acid or alcohol and has a first vapor pressure at a first temperature, and is heated by a heating element within the electronic cigarette resulting in the generation of an aerosol suitable for inhaling by the user. Often, the drug can include nicotine, but may also be configured to include cannabinol or can be associated with nicotine replacement therapies, or other medication-assisted therapies. The drugs may also have a salt or co-salt added in order to increase the effectiveness of drug delivery while lowering the need for a higher powered heating element.

A composition suitable for use in nicotine replacement therapy products includes a nicotine product that includes a synthetic nicotine that is substantially free of one or more contaminants and / or impurities normally associated with tobacco-derived nicotine. For example, the synthetic nicotine is substantially free of one or more of nicotine-1'-N-oxide, nicotyrine, nornicotyrine, 2',3-bipyridyl, cotinine, anabasine, and / or anatabine. The composition further comprises one or more pharmaceutically acceptable excipients, additives and / or carriers. The nicotine replacement therapy products may include any number of such products, including transdermal nicotine delivery patches, nicotine gums, synthetic chewing tobacco, synthetic snuff, and synthetic strips (e.g., dissolvable synthetic tobacco). Additionally, a method of treating nicotine addiction includes administering a nicotine replacement composition, e.g., via a nicotine replacement therapy product, to a user.

A method of reducing nicotine cravings is described. The method includes inhalation of a dry powder formulation containing a dose of nicotine by a subject seeking nicotine cravings reduction. The formulation includes amounts and concentrations of nicotine that are significantly lower than cigarettes or nicotine replacement therapies.

A smoking cessation device for use in nicotine replacement therapy includes an imitation smoking implement with a body sized and shaped substantially identical to a conventional smoking implement chosen from the group consisting of a cigarette, a cigarillo, a cigar, and a pipe. The device also includes one or more nicotine replacement modules removably disposed at one end of the body, the one or more nicotine replacement modules removable from the imitation smoking implement by a user to ingest said nicotine replacement modules as part of a nicotine replacement therapy. Optionally, a plurality of said imitation smoking implements can be held in a package sized and shaped to resemble a conventional box of cigarettes, cigarillos or cigars. Said imitation smoking implement can be held by the user in their hands or lips while consuming the one or more nicotine replacement modules to simulate a conventional smoking ritual.

The invention relates to the technical field of products for nicotine replacement therapy, and discloses a nicotine granule composition, which is mainly composed of nicotine immediate-release granules and nicotine sustained-release granules, wherein the components of the nicotine immediate-release granules mainly include: nicotine raw materials, fillers , binders, buffers, sweeteners and food flavors; the components of nicotine sustained-release granules mainly include: nicotine raw materials, polymer slow-release materials, binders, buffers, sweeteners and food flavors. The invention also discloses a method and a preparation device for preparing the nicotine particle mixture. The nicotine granule composition provided by the present invention can ensure the speed at which the human body obtains pleasure and the duration of nicotine in the human body to maintain a therapeutically effective concentration through the nicotine immediate-release granule and the nicotine sustained-release granule, thereby facilitating smokers to better get rid of the habit of smoking The dependence of the drug has better therapeutic effect compared with similar products sold in the existing market.

A composition suitable for use in a nicotine replacement therapy product comprising synthetic nicotine substantially free of one or more contaminants and / or impurities normally associated with tobacco-derived nicotine. For example, the synthetic nicotine is substantially free of nicotine-1'-N-oxide, nicotine diene, nicotine nordiene, 2',3-bipyridine, cotinine, anabacin and / or Or one or more of anatapin. The composition further comprises one or more pharmaceutically acceptable excipients, additives and / or carriers. Nicotine replacement therapy products may comprise any number of such products, including transdermal nicotine delivery patches, nicotine gum, synthetic chewing tobacco, synthetic snus, and synthetic tobacco rods (eg, dissolvable synthetic tobacco). Additionally, methods of treating nicotine addiction include administering a nicotine replacement composition, eg, via a nicotine replacement therapy product, to a user.